Literature DB >> 11333898

Reduced expression of HLA class II molecules and Iinterleukin-10- and transforming growth factor beta1-independent suppression of T-cell proliferation in human cytomegalovirus-infected macrophage cultures.

J Odeberg1, C Söderberg-Nauclér.   

Abstract

After a primary infection, human cytomegalovirus (HCMV) establishes lifelong latency in myeloid lineage cells, and the virus has developed several mechanisms to avoid immune recognition and destruction of infected cells. In this study, we show that HCMV utilizes two different strategies to reduce the constitutive expression of HLA-DR, -DP, and -DQ on infected macrophages and that infected macrophages are unable to stimulate a specific CD4+ T-cell response. Downregulation of the HLA class II molecules was observed in 90% of the donor samples and occurred in two phases: at an early (1 day postinfection [dpi]) time point postinfection and at a late (4 dpi) time point postinfection. The early inhibition of HLA class II expression and antigen presentation was not dependent on active virus replication, since UV-inactivated virus induced downregulation of HLA-DR and inhibition of T-cell proliferation at 1 dpi. In contrast, the late effect required virus replication and was dependent on the expression of the HCMV unique short (US) genes US1 to -9 or US11 in 77% of the samples. HCMV-treated macrophages were completely devoid of T-cell stimulation capacity at 1 and 4 dpi. However, while downregulation of HLA class II expression was rather mild, a 66 to 90% reduction in proliferative T-cell response was observed. This discrepancy was due to undefined soluble factors produced in HCMV-infected cell cultures, which did not include interleukin-10 and transforming growth factor beta1. These results suggest that HCMV reduces expression of HLA class II molecules on HCMV-infected macrophages and inhibits T-cell proliferation by different distinct pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333898      PMCID: PMC114922          DOI: 10.1128/JVI.75.11.5174-5181.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction.

Authors:  D M Miller; Y Zhang; B M Rahill; W J Waldman; D D Sedmak
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 2.  Cytomegalovirus infection and disease after bone marrow transplantation: epidemiology, prevention, and treatment.

Authors:  P Reusser
Journal:  Bone Marrow Transplant       Date:  1991       Impact factor: 5.483

3.  Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts.

Authors:  C Cerboni; M Mousavi-Jazi; A Linde; K Söderström; M Brytting; B Wahren; K Kärre; E Carbone
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

4.  Plaque assay of cytomegalovirus strains of human origin.

Authors:  B B Wentworth; L French
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

5.  Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10.

Authors:  S Redpath; A Angulo; N R Gascoigne; P Ghazal
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

6.  Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40.

Authors:  P Tomasec; V M Braud; C Rickards; M B Powell; B P McSharry; S Gadola; V Cerundolo; L K Borysiewicz; A J McMichael; G W Wilkinson
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

7.  Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression.

Authors:  E Le Roy; A Mühlethaler-Mottet; C Davrinche; B Mach; J L Davignon
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression.

Authors:  D D Sedmak; W H Roberts; R E Stephens; W J Buesching; L A Morgan; D H Davis; W J Waldman
Journal:  Transplantation       Date:  1990-02       Impact factor: 4.939

9.  Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells.

Authors:  R Tomazin; J Boname; N R Hegde; D M Lewinsohn; Y Altschuler; T R Jones; P Cresswell; J A Nelson; S R Riddell; D C Johnson
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

10.  Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA.

Authors:  J M Fletcher; H G Prentice; J E Grundy
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

View more
  16 in total

1.  Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.

Authors:  Laura Hertel; Vashti G Lacaille; Herbert Strobl; Elizabeth D Mellins; Edward S Mocarski
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 2.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation.

Authors:  Carina Bayer; Stefania Varani; Li Wang; Paul Walther; Shaoxia Zhou; Sarah Straschewski; Max Bachem; Cecilia Söderberg-Naucler; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

4.  Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.

Authors:  Chuan-ging Wu; Anuradha Budhu; Sheng Chen; Xiaoling Zhou; Nicholas C Popescu; Kristoffer Valerie; Xin Wei Wang
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

5.  Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels.

Authors:  Andrew W Lee; Nan Wang; Tara M C Hornell; James J Harding; Chetan Deshpande; Laura Hertel; Vashti Lacaille; Achal Pashine; Claudia Macaubas; Edward S Mocarski; Elizabeth D Mellins
Journal:  Mol Immunol       Date:  2011-03-31       Impact factor: 4.407

6.  The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins.

Authors:  Jenny Odeberg; Helena Browne; Sunil Metkar; Christopher J Froelich; Lars Brandén; David Cosman; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.

Authors:  Chris A Benedict; Andrea Loewendorf; Zacarias Garcia; Bruce R Blazar; Edith M Janssen
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

8.  Rat cytomegalovirus infection depletes MHC II in bone marrow derived dendritic cells.

Authors:  Carmen C Baca Jones; Craig N Kreklywich; Ilhem Messaoudi; Jennifer Vomaske; Erin McCartney; Susan L Orloff; Jay A Nelson; Daniel N Streblow
Journal:  Virology       Date:  2009-04-05       Impact factor: 3.616

Review 9.  Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Sheling Xie; Kaifei Wang; Wei Zhang; Kun Xiao; Peng Yan; Yanqin Li; Wanxue He; Yuhan Zhang; Lixin Xie
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

10.  Cytomegalovirus infection induces production of human interleukin-10 in macrophages.

Authors:  I Nordøy; H Rollag; E Lien; H Sindre; M Degré; P Aukrust; S S Frøland; F Müller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.